Selinexor (KPT-330) Infosheet

This Horizons Infosheet contains information on Selinexor (originally known as KPT-330), a drug being investigated for the treatment of myeloma. 

This Horizons Infosheet contains information on Selinexor (originally known as KPT-330), a drug being investigated for
the treatment of myeloma.

Selinexor is the first in a new family of drugs known as Selective Inhibitor of Nuclear Export (SINE™) compounds. Selinexor works by blocking the action of a protein called XPO1 within the nucleus (centre compartment) of myeloma cells.

Selinexor is given in tablet form. Selinexor can be given on its own as a monotherapy but it has shown to be most effective when used in combination with other anti-myeloma treatments such as dexamethasone.

Early stage clinical trials to date have shown that Selinexor can produce effective responses in myeloma patients who are
relapsed and/or refractory to several prior treatments. More detail on the results of recent trials are included in the infosheet.

The most commonly observed side-effects of Selinexor include nausea, vomiting, loss of appetite and fatigue. Some  patients also experience low platelet levels (thrombocytopenia).

In 2014, Selinexor was granted “orphan drug designation” by the European Medicines Agency (EMA) for myeloma. This means that the EMA will offer the drug company certain financial incentives throughout the development and licensing
process in order to enable selinexor to become available to patients sooner. Therefore, selinexor is not currently licensed for use in myeloma in the UK and is only accessible to patients as part of a clinical trial.

For an up-to-date list of UK clinical trials involving Selinexor, visit the Myeloma Trial Finder on

Selinexor continues to be studied in different patient groups and in different combinations. It has an entirely different way of working from other anti-myeloma drugs, and therefore offers hope for multiply relapsed and/or refractory patients. Selinexor has also shown promising initial results in high-risk patients whose myeloma is particularly resistant
to the effects of treatment.